190 related articles for article (PubMed ID: 34981653)
1. The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions.
Ma M; Zhu J; Yang Y; Wang X; Jin Y; Zhang J; Wu S
Cancer Med; 2022 Mar; 11(6):1542-1552. PubMed ID: 34981653
[TBL] [Abstract][Full Text] [Related]
2. Characterization of HPV subtypes not covered by the nine-valent vaccine in patients with CIN 2-3 and cervical squamous cell carcinoma.
Ma MJ; Wang YN; Zhu JF; Wang XY; Jin YB; Liu XN; Wu SF; Yang YB
Curr Probl Cancer; 2021 Dec; 45(6):100761. PubMed ID: 34154817
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
[TBL] [Abstract][Full Text] [Related]
5. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
Joura EA; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris D; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Miller D; Monsonego J; Munoz N; Myers E; Paavonen J; Pitisuttithum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1997-2008. PubMed ID: 25274978
[TBL] [Abstract][Full Text] [Related]
6. Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China.
Wang H; Cheng X; Ye J; Xu X; Hong Y; Sui L; You Z; Xie X
BMC Cancer; 2018 Apr; 18(1):487. PubMed ID: 29703167
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
8. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
9. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis.
Zhang J; Cheng K; Wang Z
Arch Gynecol Obstet; 2020 Dec; 302(6):1329-1337. PubMed ID: 32914222
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of single human papillomavirus 53 infection: a retrospective study of 419 cases.
Chen R; Fu Y; You B; Li Y; Yao Y; Wang X; Cheng X
BMC Infect Dis; 2021 Nov; 21(1):1158. PubMed ID: 34781884
[TBL] [Abstract][Full Text] [Related]
12. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
14. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China.
Chan PK; Cheung TH; Li WH; Yu MY; Chan MY; Yim SF; Ho WC; Yeung AC; Ho KM; Ng HK
Int J Cancer; 2012 Aug; 131(3):692-705. PubMed ID: 21976212
[TBL] [Abstract][Full Text] [Related]
15. Respective prevalence of high-risk HPVgenotypes in cervical neoplasia in Senegal.
Diop-Ndiaye H; Sastre-Garau X; Drame A; Dembele B; Ba NN; Diop-Diongue O; Mbow M; Diakhaby MEB; Woto-Gaye G; Toure Kane C; Diop M
J Med Virol; 2021 Aug; 93(8):5110-5117. PubMed ID: 33851737
[TBL] [Abstract][Full Text] [Related]
16. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
17. Candidate HPV genotypes not included in the 9-valent vaccine for prevention of CIN 2-3.
Gonzalez-Bosquet E; Gibert M; Serra M; Hernandez-Saborit A; Gonzalez-Fernandez A
Int J Gynecol Cancer; 2020 Jul; 30(7):954-958. PubMed ID: 32467333
[TBL] [Abstract][Full Text] [Related]
18. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai, China revealed the limitations of current HPV-based screening and HPV vaccine.
Ruan Y; Li H; Liu M; Cao G; Xu X; Han L; Li F
Cancer Epidemiol; 2023 Jun; 84():102372. PubMed ID: 37119603
[TBL] [Abstract][Full Text] [Related]
20. Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016.
Welby S; Rosillon D; Feng Y; Borys D
Expert Rev Vaccines; 2022 Mar; 21(3):407-413. PubMed ID: 34939897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
